Healthcare Services

Paroxysmal Nocturnal Hemoglobinuria (PNH) Industry Growth Insights: Revenue Forecast to 2030

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the paroxysmal nocturnal hemoglobinuria (pnh) market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The market for paroxysmal nocturnal hemoglobinuria (pnh) has shown robust growth in recent years. It is anticipated to increase from $4.67 billion in 2025 to $5.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. This past growth can be attributed to the scarcity of effective targeted therapies, challenges in diagnosis due to the disease’s rarity, a dependency on supportive care and transfusions, the elevated mortality rates associated with untreated pnh, and insufficient awareness among general healthcare providers.

The paroxysmal nocturnal hemoglobinuria (pnh) market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to attain a valuation of $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This projected growth stems from factors such as the creation of advanced complement inhibitors, an uptick in diagnosis rates facilitated by sophisticated testing, a heightened emphasis on therapies for orphan diseases, greater access to specialized hematology centers, and an increase in reimbursement coverage for rare disease treatments. Noteworthy developments during this period are expected to include a surge in the adoption of complement inhibitor therapies, expanded utilization of flow cytometry for accurate diagnosis, the proliferation of long-acting monoclonal antibody treatments, the broadening of specialized rare hematology care programs, and enhanced strategies for managing thrombosis and hemolysis complications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp

What Drivers Are Supporting Technological Adoption In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The increasing occurrence of blood and bone marrow-related disorders is projected to fuel the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood disorders are medical ailments that affect the make-up, function, and production of blood and its various components. Bone marrow-related disorders arise when there is insufficient production of red, white, or platelets in the bone marrow, or when the blood cells generated are either damaged or defective. PNH is intimately linked to blood disorders and bone marrow-related disorders due to its effects on blood cell generation, immune system performance, and the microenvironment of the bone marrow. It is a rare blood condition associated with bone marrow failure diseases, occurring due to a genetic flaw that impacts the functionality of red blood cells and platelets. For instance, Blood Cancer United, a UK-based nonprofit advocacy group dedicated to raising awareness and support for blood cancer patients, forecasts that in 2025, approximately 192,070 individuals in the U.S. are expected to receive a diagnosis of leukemia, lymphoma, or myeloma. Therefore, the rising incidence of blood disorders and bone marrow-related disorders is stimulating the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

What Segment Types Are Examined In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The paroxysmal nocturnal hemoglobinuria (pnh) market covered in this report is segmented –

1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types

2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types

3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications

2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation

3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion

4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil

5) By Other Treatment Types: Supportive Therapies, Management Of Complications

Which Trends Are Influencing The Performance And Direction Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Major companies active in the paroxysmal nocturnal hemoglobinuria (PNH) market are prioritizing the development of new and innovative drugs and therapies, such as injectable C5 inhibitors for the management of paroxysmal nocturnal hemoglobinuria (PNH), to maintain their standing in the market. An injectable C5 inhibitor is a monoclonal antibody designed to block the complement component C5, thereby reducing inflammation and tissue damage in autoimmune diseases and conditions like paroxysmal nocturnal hemoglobinuria (PNH). For instance, in February 2024, Chugai Pharmaceutical Co., a pharmaceutical company headquartered in Japan, secured priority review approval from China’s National Medical Products Administration (NMPA) for treating paroxysmal nocturnal hemoglobinuria (PNH). This development establishes China as the first country to approve PIASKY, ahead of other key markets, allowing it to commence National Reimbursement Drug List (NRDL) negotiations within the same year. PNH, categorized as a rare disease, affects an estimated 12,740 individuals in China, indicating considerable market potential.

Who Are The Top-Performing Companies In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In Recent Years?

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc, Novartis AG, Thermo Fisher Scientific Inc, GE Healthcare, Grifols S.A, Genentech Inc, Bioverativ Inc, BioCryst Pharmaceuticals, Hansa Biopharma AB, Apellis Pharmaceuticals Inc, Akari Therapeutics Plc, RA Pharmaceuticals Inc, C5 Therapeutics Inc, Omeros Corporation, Amyndas Pharmaceuticals SA, CANbridge Pharmaceuticals, NovelMed Therapeutics Inc, Annexon Inc, Dianthus Therapeutics, DynamiCure Biotechnology, Kira Pharmaceuticals Ltd, Kyowa Kirin Co Ltd, Swedish Orphan Biovitrum AB, Arrowhead Pharmaceuticals, ReAlta Life Sciences, Q32 Bio, ISU Abxis

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2025. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12936&type=smp

Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market 2026, By The Business Research Company

Hemoglobin A1C Hba1C Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemoglobin-a1c-hba1c-testing-global-market-report

Hemoglobin Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemoglobin-testing-global-market-report

Hemoglobinopathies Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795